Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo

Juliette Fremaux, Claire Venin, Laura Mauran, Robert H. Zimmer, Gilles Guichard () and Sébastien R. Goudreau ()
Additional contact information
Juliette Fremaux: UREKA—ImmuPharma Group
Claire Venin: UREKA—ImmuPharma Group
Laura Mauran: UREKA—ImmuPharma Group
Robert H. Zimmer: UREKA—ImmuPharma Group
Gilles Guichard: Univ. Bordeaux, CNRS, CBMN, UMR 5248, Institut Européen de Chimie et Biologie
Sébastien R. Goudreau: UREKA—ImmuPharma Group

Nature Communications, 2019, vol. 10, issue 1, 1-9

Abstract: Abstract Peptides have gained so much attention in the last decade that they are now part of the main strategies, with small molecules and biologics, for developing new medicines. Despite substantial progress, the successful development of peptides as drugs still requires a number of limitations to be addressed, including short in vivo half-lives and poor membrane permeability. Here, we describe the use of oligourea foldamers as tool to improve the pharmaceutical properties of GLP-1, a 31 amino acid peptide hormone involved in metabolism and glycemic control. Our strategy consists in replacing four consecutive amino acids of GLP-1 by three consecutive ureido residues by capitalizing on the structural resemblance of oligourea and α-peptide helices. The efficacy of the approach is demonstrated with three GLP-1-oligourea hybrids showing prolonged activity in vivo. Our findings should enable the use of oligoureas in other peptides to improve their pharmaceutical properties and may provide new therapeutic applications.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-08793-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-08793-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-08793-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().